ArticleOncology letters2018
Prognostic significance of ANLN in lung adenocarcinoma.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 65 citations in OpenAlex.
- A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.Immuno-oncology technology · 2026Article
- Circulating Plasma Circular RNAs hsa_circ_0001785 and hsa_circ_0079876 as Promising Noninvasive Diagnostic Biomarkers for Breast Cancer: A Case-Control Study.The breast journal · 2026Article
- Identification of prognostic genes associated with phase separation in lung adenocarcinoma and construction of prognostic models.Scientific reports · 2025Article
- Expression pattern and prognostic significance of aldehyde dehydrogenase 2 in lung adenocarcinoma as a potential predictor of immunotherapy efficacy.Cancer innovation · 2025Article
- Identification of novel molecular subtypes and construction of a prognostic signature via multi-omics analysis and machine learning in lung adenocarcinoma.Frontiers in oncology · 2025Article
- Single-Cell Transcriptomic Profiling Reveals KRAS/TP53-Driven Neutrophil Reprogramming in Luad: A Multi-Gene Prognostic Model and Therapeutic Targeting of RHOV.Oncology research · 2025Article
- Article
- Article
- Auricular fistula: a review of its clinical manifestations, genetics, and treatments.Journal of molecular medicine (Berlin, Germany) · 2023Review
- Identification and validation of novel prognostic biomarkers and therapeutic targets for non-small cell lung cancer.Frontiers in genetics · 2023Article
- Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma.Scientific reports · 2022Article
- Exosomal LINC00460/miR-503-5p/ANLN positive feedback loop aggravates pancreatic cancer progression through regulating T cell-mediated cytotoxicity and PD-1 checkpoint.Cancer cell international · 2022Article
- Article
- Identifying the genes impacted by cell proliferation in proteomics and transcriptomics studies.PLoS computational biology · 2022Article
- Anillin governs mitotic rounding during early epidermal development.BMC biology · 2022Article
- RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.Scientific reports · 2022Article
- Raising of Anillin expression in para-cancerous hepatocytes is associated with hepatic depolyploidization and short-term recurrence of hepatocellular carcinoma after radical operation.Journal of Cancer · 2022Article
- Comprehensive Analysis of ANLN in Human Tumors: A Prognostic Biomarker Associated with Cancer Immunity.Oxidative medicine and cellular longevity · 2022Article
- A Four-Gene Prognostic Signature Based on the TEAD4 Differential Expression Predicts Overall Survival and Immune Microenvironment Estimation in Lung Adenocarcinoma.Frontiers in pharmacology · 2022Article
- Comprehensive bioinformatics analysis reveals the prognostic value, predictive value, and immunological roles of ANLN in human cancers.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anillin actin binding protein (ANLN) is a biomarker of cancer progression and is overexpressed in lung adenocarcinoma. The aim of the present study was to investigate the role of ANLN protein and RNA in the development of lung adenocarcinoma. The ANLN protein sequence was downloaded from The National Centre for Biotechnology information, RNA sequencing (RNA-seq) data was obtained from The Cancer Genome Atlas database. All immunohistochemical staining pictures were adapted from the Human Protein Atlas. PyMOL software was employed to predict protein functional changes in response to mutations. Gene Set Enrichments Analysis was employed for pathway analysis. The results indicated that ANLN experiences genetic change and overexpression at the RNA and protein levels in patients with lung adenocarcinoma. Kaplan-Meier survival curve analysis revealed significant differences between high and low RNA-seq expression levels in ANLN, and patients exhibiting higher expression of ANLN had a relatively poor prognosis. Pathway analysis demonstrated that ANLN was involved in developmental processes via the regulation of nuclear division' pathway. In conclusion, ANLN has potential for use as a diagnostic and prognostic biomarker to diagnoseand predict the outcome of lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.